|1.||McMurray, John J V: 22 articles (10/2015 - 09/2004)|
|2.||Solomon, Scott D: 18 articles (10/2015 - 10/2004)|
|3.||Bakris, George L: 18 articles (09/2015 - 01/2002)|
|4.||Fonarow, Gregg C: 16 articles (11/2015 - 01/2002)|
|5.||Swedberg, Karl: 16 articles (10/2015 - 08/2003)|
|6.||Xia, Yang: 15 articles (01/2015 - 08/2007)|
|7.||Yusuf, Salim: 15 articles (02/2013 - 10/2004)|
|8.||Schiffrin, Ernesto L: 14 articles (01/2016 - 03/2002)|
|9.||Sasamura, Hiroyuki: 14 articles (10/2015 - 08/2002)|
|10.||Rakugi, Hiromi: 14 articles (01/2015 - 01/2002)|
|1.||Hypertension (High Blood Pressure)
09/01/2001 - "An angiotensin receptor blocker plus a diuretic is most effective in lowering blood pressure in the African American with hypertension on a supplemental salt diet."
05/01/2014 - "Fimasartan, the eighth angiotensin receptor blocker, was launched in March 2011 and was found to have an excellent efficacy and safety profile in a large cross-sectional population study [Safety and Efficacy of Fimasartan in Patients with Arterial Hypertension (Safe-KanArb); Park et al.: Am J Cardiovasc Drugs 2013;13:47-56]. "
09/01/2003 - "A new study demonstrates that angiotensin-induced hypertension results in a marked decrease in expression of the beta subunit of the BK channel, suggesting a role for this critical subunit in the regulation of vascular tone."
07/01/2015 - "Angiotensin inhibitors have not been effective in slowing progression, although avoidance of nephrotoxins and timely treatment of hypertension are important. "
09/01/2011 - "The results of animal experiments from our and other laboratories have suggested that vaccination against the angiotensin type 1 (AT1) receptor causes a significant decrease in blood pressure in animal models of hypertension, and also ameliorates hypertensive end-organ damage. "
03/01/1999 - "This new conceptual model has first led to the widespread introduction of angiotensin converting inhibitors in clinical practice; then, the evidence that sympathetic activation might play an important role in the progression of heart failure, led the investigators to propose that beta-blocking agents might be useful in the management of heart failure. "
01/01/2013 - "The improvement in microcirculatory perfusion observed with angiotensin inhibitors in patients with severe heart failure may partially explain the beneficial clinical effects of this intervention in such patients."
05/01/2015 - "Reduction of angiotensin inhibition in older CKD patients with heart failure led to improved renal and mortality outcomes - the results of a Spanish open RCT."
01/01/2013 - "In patients with severe heart failure, introduction of angiotensin antagonist therapy was associated with an early improvement in the microcirculation that persisted over subsequent hours. "
05/01/2015 - "An historical survey is presented of mortality trials on angiotensin-aldosteron system inhibition in patients with chronic heart failure. "
12/01/2014 - "All the subjects had a marked decrease in proteinuria after angiotensin receptor blocker (ARB) treatment. "
02/01/2007 - "Inclusion criteria were adults and children 13 years and older with biopsy-proven idiopathic FSGS, proteinuria with protein of 3.5 g/d or greater while on angiotensin antagonist therapy, glomerular filtration rate (GFR) of 30 mL/min/1.73 m(2) or greater (>or=0.50 mL/s), and failure to achieve sustained remission with at least 1 immunosuppressive agent. "
12/01/2011 - "With therapy for WM and the addition of an angiotensin receptor blocker, the patient's proteinuria also improved, from 7.8 g to 4.8 g/24 h. "
01/01/2010 - "With the administration of intensive therapies, including angiotensin type 1-receptor blocker and some lipid lowering drugs, along with traditional dietary therapy, daily proteinuria of the patient improved from 2.1 g to 0.78 g. "
06/01/2012 - "In the present study, we tested whether the effects of monotherapy with an angiotensin receptor blocker (ARB) to lower proteinuria could be restricted by reduced GFR. "
|4.||Cardiovascular Diseases (Cardiovascular Disease)
01/01/2003 - "Pharmacological suppression of the RAS, through ACE inhibition and/or angiotensin receptor blockade, is a proven effective therapeutic approach to the treatment of a range of cardiovascular diseases. "
04/01/2009 - "A large ongoing study is investigating whether the treatment with an oral antidiabetic drug or an angiotensin-receptor blocker will reduce the incidence of new-onset diabetes and cardiovascular disease in patients at high risk for developing diabetes."
05/01/2000 - "New clinical trials of angiotensin blockade in cardiovascular disease: foreword."
08/01/2013 - "Analysis of strain-specific selective sweeps and gene clusters implicated genes and pathways involved in cation transport, angiotensin production, and regulators of oxidative stress in the development of cardiovascular disease phenotypes in rats. "
06/01/2013 - "Angiotensin (Ang) II is critically involved in multiple cardiovascular diseases mainly through the Ang II type 1 (AT1) receptor. "
06/01/2007 - "Recent experimental studies have shown that the brain RAS plays an important role in stroke and neuronal protection through its effector peptide angiotensin (Ang) II. Ang II exerts its stroke-protective effects through stimulation of Ang II type 2 (AT2) receptors. "
01/01/2007 - "Finally, a cautious view for the practicing nephrologist is expressed, highlighting the difference between study patients and real-life patients, and the possible overlooked aspects of recent renal protection studies (the importance of central blood pressure, of ambulatory blood pressure monitoring and possible, the impact of angiotensin converting inhibitors on stroke), are presented."
01/01/2002 - "In the present study, we examined developmental changes of angiotensin receptor subtypes in the kidney of stroke-prone spontaneously hypertensive rats (SHRSP), and compared them with those in normotensive Wistar-Kyoto rats (WKY). "
01/01/2015 - "In conclusion, angiotensin receptor blocker (ARB) and CCB combination may be preferable to an ARB and diuretic combination in the very elderly hypertensive patients for the reduction of cardiovascular risk, particularly for the reduction in stroke risk."
01/01/2015 - "Neuroprotection after ischemic stroke by activation of angiotensin receptor type 2: why clinical data do not fit the paradigm?"
|2.||Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)
|4.||Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
|9.||Neprilysin (Neutral Endopeptidase)
|10.||Calcium Channels (Calcium Channel)
|1.||Cardiac Resynchronization Therapy
|2.||Transplantation (Transplant Recipients)
|3.||Implantable Defibrillators (Implantable Cardioverter-Defibrillator)